Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

A characterization of the relationship of ovarian reserve markers with age.

Rosen MP, Johnstone E, McCulloch CE, Schuh-Huerta SM, Sternfeld B, Reijo-Pera RA, Cedars MI.

Fertil Steril. 2012 Jan;97(1):238-43. doi: 10.1016/j.fertnstert.2011.10.031.

2.

A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation.

Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N.

Fertil Steril. 2010 Feb;93(3):855-64. doi: 10.1016/j.fertnstert.2008.10.042.

PMID:
19046583
3.

Correlation of ovarian reserve tests with histologically determined primordial follicle number.

Hansen KR, Hodnett GM, Knowlton N, Craig LB.

Fertil Steril. 2011 Jan;95(1):170-5. doi: 10.1016/j.fertnstert.2010.04.006.

PMID:
20522327
4.

Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure.

Knauff EA, Eijkemans MJ, Lambalk CB, ten Kate-Booij MJ, Hoek A, Beerendonk CC, Laven JS, Goverde AJ, Broekmans FJ, Themmen AP, de Jong FH, Fauser BC; Dutch Premature Ovarian Failure Consortium..

J Clin Endocrinol Metab. 2009 Mar;94(3):786-92. doi: 10.1210/jc.2008-1818. Erratum in: J Clin Endocrinol Metab. 2010 Jan;95(1):465.

PMID:
19066296
5.

Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome.

Eldar-Geva T, Ben-Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T, Gal M, Zylber-Haran E, Margalioth EJ.

Hum Reprod. 2005 Nov;20(11):3178-83.

PMID:
16113044
6.

Impact of cancer therapies on ovarian reserve.

Gracia CR, Sammel MD, Freeman E, Prewitt M, Carlson C, Ray A, Vance A, Ginsberg JP.

Fertil Steril. 2012 Jan;97(1):134-40.e1. doi: 10.1016/j.fertnstert.2011.10.040.

8.

Effect of laparoscopic excision of endometriomas on ovarian reserve: serial changes in the serum antimüllerian hormone levels.

Celik HG, Dogan E, Okyay E, Ulukus C, Saatli B, Uysal S, Koyuncuoglu M.

Fertil Steril. 2012 Jun;97(6):1472-8. doi: 10.1016/j.fertnstert.2012.03.027.

PMID:
22521696
9.

Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.

Tsakos E, Tolikas A, Daniilidis A, Asimakopoulos B.

Arch Gynecol Obstet. 2014 Dec;290(6):1249-53. doi: 10.1007/s00404-014-3332-3.

PMID:
25001569
10.

[Estimation of ovarian response using multiple predictors of ovarian reserve in women undergoing in vitro fertilization-embryo transfer].

He Y, Xia R, Chen X, Ye D, Tang Y, Li P, Niu J, Chen S.

Nan Fang Yi Ke Da Xue Xue Bao. 2013 Feb;33(2):216-20. Chinese.

11.

Serum anti-müllerian hormone, follicle stimulating hormone and antral follicle count measurement cannot predict pregnancy rates in IVF/ICSI cycles.

Sahmay S, Demirayak G, Guralp O, Ocal P, Senturk LM, Oral E, Irez T.

J Assist Reprod Genet. 2012 Jul;29(7):589-95. doi: 10.1007/s10815-012-9754-6.

12.

Prospective study into the value of the automated Elecsys antimüllerian hormone assay for the assessment of the ovarian growing follicle pool.

Anderson RA, Anckaert E, Bosch E, Dewailly D, Dunlop CE, Fehr D, Nardo L, Smitz J, Tremellen K, Denk B, Geistanger A, Hund M.

Fertil Steril. 2015 Apr;103(4):1074-1080.e4. doi: 10.1016/j.fertnstert.2015.01.004.

13.

Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles.

Ocal P, Sahmay S, Cetin M, Irez T, Guralp O, Cepni I.

J Assist Reprod Genet. 2011 Dec;28(12):1197-203. doi: 10.1007/s10815-011-9627-4.

14.

Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.

Partridge AH, Ruddy KJ, Gelber S, Schapira L, Abusief M, Meyer M, Ginsburg E.

Fertil Steril. 2010 Jul;94(2):638-44. doi: 10.1016/j.fertnstert.2009.03.045.

PMID:
19409543
15.

Prospective analysis of ovarian reserve markers as determinant in response to controlled ovarian stimulation in women undergoing IVF cycles in low resource setting in India.

Singh N, Bahadur A, Malhotra N, Kalaivani M, Mittal S.

Arch Gynecol Obstet. 2013 Sep;288(3):697-703. doi: 10.1007/s00404-013-2802-3.

PMID:
23529683
16.

Anti-müllerian hormone is a promising predictor for the occurrence of the menopausal transition.

van Rooij IA, Tonkelaar Id, Broekmans FJ, Looman CW, Scheffer GJ, de Jong FH, Themmen AP, te Velde ER.

Menopause. 2004 Nov-Dec;11(6 Pt 1):601-6.

PMID:
15545787
17.

Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology?

Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P.

BJOG. 2005 Oct;112(10):1384-90.

18.

Chronological age vs biological age: an age-related normogram for antral follicle count, FSH and anti-Mullerian hormone.

Wiweko B, Prawesti DM, Hestiantoro A, Sumapraja K, Natadisastra M, Baziad A.

J Assist Reprod Genet. 2013 Dec;30(12):1563-7. doi: 10.1007/s10815-013-0083-1.

19.

Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study.

van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, Fauser BJ, Themmen AP, te Velde ER.

Fertil Steril. 2005 Apr;83(4):979-87.

PMID:
15820810
20.

Clinical pregnancy in a woman with idiopathic hypogonadotropic hypogonadism and low AMH: utility of ovarian reserve markers in IHH.

Chan C, Liu K.

J Assist Reprod Genet. 2014 Oct;31(10):1317-21. doi: 10.1007/s10815-014-0312-2.

Supplemental Content

Support Center